Barton Investment Management Has $1.65 Million Holdings in AbbVie Inc. $ABBV

Barton Investment Management decreased its position in shares of AbbVie Inc. (NYSE:ABBV) by 21.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,578 shares of the company’s stock after selling 2,036 shares during the period. AbbVie makes up 0.2% of Barton Investment Management’s holdings, making the stock its 27th biggest position. Barton Investment Management’s holdings in AbbVie were worth $1,648,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of ABBV. Chelsea Counsel Co. acquired a new position in shares of AbbVie during the 3rd quarter worth approximately $26,000. Litman Gregory Wealth Management LLC acquired a new stake in shares of AbbVie in the fourth quarter valued at approximately $28,000. Westend Capital Management LLC bought a new stake in shares of AbbVie in the fourth quarter valued at approximately $29,000. Imprint Wealth LLC lifted its position in AbbVie by 56.2% during the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after purchasing an additional 45 shares during the period. Finally, Texas Capital Bancshares Inc TX acquired a new stake in AbbVie during the third quarter worth about $31,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Stock Performance

Shares of NYSE ABBV opened at $251.52 on Friday. The company’s 50 day moving average price is $215.16 and its 200-day moving average price is $219.18. AbbVie Inc. has a 52-week low of $181.73 and a 52-week high of $253.35. The company has a market capitalization of $444.38 billion, a P/E ratio of 123.90, a price-to-earnings-growth ratio of 0.74 and a beta of 0.32.

AbbVie (NYSE:ABBV) last announced its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, topping analysts’ consensus estimates of $2.59 by $0.06. The business had revenue of $15 billion during the quarter, compared to the consensus estimate of $14.72 billion. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. AbbVie’s quarterly revenue was up 12.4% on a year-over-year basis. During the same quarter last year, the firm earned $2.46 earnings per share. Analysts forecast that AbbVie Inc. will post 14.28 earnings per share for the current year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend is Wednesday, July 15th. AbbVie’s dividend payout ratio is 340.89%.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie said the FDA approved Skyrizi for pediatric use in psoriatic disease, making it the first and only IL-23 inhibitor in the U.S. approved for children six years and older weighing less than 40 kg with plaque psoriasis or psoriatic arthritis. The expansion broadens the drug’s addressable market and supports long-term sales growth. Article: SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease
• Positive Sentiment: AbbVie’s Apogee Therapeutics acquisition is being viewed favorably by analysts, with Canaccord raising its price target and saying the deal strengthens AbbVie’s long-term growth outlook by adding promising pipeline assets. Article: AbbVie Just Sparked a 46% Rally in Apogee. Here’s Why This $10.9 Billion Deal Could Be a Win for AbbVie Investors.
• Positive Sentiment: AbbVie is also benefiting from broader healthcare sector strength, with shares hitting new highs as investors rotate into defensive large-cap pharma names. Article: Lilly, J&J, AbbVie hit all-time highs as healthcare outperforms
• Neutral Sentiment: AbbVie announced it will host its second-quarter 2026 earnings call on July 31, which is a standard investor update and does not by itself change fundamentals. Article: AbbVie to Host Second-Quarter 2026 Earnings Conference Call
• Neutral Sentiment: Commentary pieces also highlighted AbbVie’s recent pediatric label expansions in Europe for Skyrizi and Maviret, reinforcing the company’s shift toward earlier-disease and younger-patient growth opportunities. Article: Will AbbVie’s (ABBV) Pediatric Expansions Reveal a Deeper Shift in Its Growth Mix?

Analyst Upgrades and Downgrades

ABBV has been the subject of a number of recent analyst reports. Morgan Stanley upped their price target on shares of AbbVie from $270.00 to $278.00 and gave the stock an “overweight” rating in a report on Thursday, April 30th. Wall Street Zen raised AbbVie from a “buy” rating to a “strong-buy” rating in a report on Saturday. DZ Bank raised AbbVie from a “hold” rating to a “strong-buy” rating in a report on Thursday, April 30th. BMO Capital Markets restated an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Finally, Wells Fargo & Company set a $260.00 price objective on AbbVie in a research note on Monday. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $253.81.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.